Akeso Enters into Collaboration with Summit Therapeutics and Pfizer to Develop Ivonescimab and ADCs
Tuesday, February 25, 2025
Akeso has announced a collaboration with Summit Therapeutics and Pfizer.
Ivonescimab is a PD-1/VEGF bispecific immunotherapy developed by Akeso. In Summit Therapeutics’ licensed territories—including the United States, Canada, Europe, Japan, Central and South America, the Middle East, and Africa—it is referred to as SMT112.
Ivonescimab has received marketing approval in China for the treatment of EGFR-mutated, locally advanced, or metastatic non-squamous non-small cell lung cancer (NSCLC) after EGFR TKI therapy.
Akeso is conducting six registrational trials comparing ivonescimab to PD-1/L1 therapies, alongside multiple clinical studies covering 17 indications, including gastrointestinal cancer, hepatocellular carcinoma, and colorectal cancer.
The collaboration aims to evaluate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with several of Pfizer's antibody-drug conjugates (ADCs) for treating solid tumours.
The partnership is intended to explore the potential of these drug combinations to improve treatment options for patients with high medical needs. The studies will assess the safety and effectiveness of ivonescimab when combined with Pfizer’s vedotin ADCs in distinct tumour types.
Under the agreement, Summit will provide ivonescimab, while Pfizer will oversee the clinical trials. Both companies will retain the rights to their respective products.
The trials are expected to commence in mid-2025, with further details to be disclosed later.
Source: akesobio.com
